Circulating sCD14 Is Associated with Virological Response to Pegylated-Interferon-Alpha/Ribavirin Treatment in HIV/HCV Co-Infected Patients

Giulia Marchetti1*, Paola Nasta2*, Francesca Bai1, Francesca Gatti2, Giusi Maria Bellistrì1, Camilla Tincati1, Federica Borghi2, Giampiero Carosi2, Massimo Puoti3, Antonella d’Arminio Monforte1

1 Department of Medicine, Surgery and Dentistry, Clinic of Infectious Diseases and Tropical Medicine, University of Milan, San Paolo Hospital, Milan, Italy, 2 Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy, 3 Department of Infectious Diseases, A.O. Ospedale Niguarda Cà Granda, Milan, Italy

Abstract

Objectives: Microbial translocation (MT) through the gut accounts for immune activation and CD4+ loss in HIV and may influence HCV disease progression in HIV/HCV co-infection. We asked whether increased MT and immune activation may hamper anti-HCV response in HIV/HCV patients.

Methods: 98 HIV/HCV patients who received pegylated-alpha-interferon (peg-INF-alpha)/ribavirin were retrospectively analyzed. Baseline MT (lipopolysaccharide, LPS), host response to MT (sCD14), CD38+HLA-DR+CD4+/CD8+, HCV genotype, severity of liver disease were assessed according to Early Virological Response (EVR: HCV-RNA <50 IU/mL at week 12 of therapy or ≥2 log10 reduction from baseline after 12 weeks of therapy) and Sustained Virological Response (SVR: HCV-RNA <50 IU/mL 24 weeks after end of therapy). Mann-Whitney/Chi-square test and Pearson’s correlation were used. Multivariable regression was performed to determine factors associated with EVR/SVR.

Results: 71 patients displayed EVR; 41 SVR. Patients with HCV genotypes 1–4 and cirrhosis presented a trend to higher sCD14, compared to patients with genotypes 2–3 (p = 0.053) and no cirrhosis (p = 0.052). EVR and SVR patients showed lower levels of circulating sCD14 (p = 0.0001, p = 0.026, respectively), but similar T-cell activation compared to Non-EVR (Null Responders, NR) and Non-SVR (N-SVR) subjects. sCD14 resulted the main predictive factor of EVR (0.145 for each sCD14 unit more, 95%CI 0.031–0.688, p = 0.015). SVR was associated only with HCV genotypes 2–3 (AOR 0.022 for genotypes 1–4 vs 2–3, 95%CI 0.001–0.469, p = 0.014).

Conclusions: In HIV/HCV patients sCD14 correlates with the severity of liver disease and predicts early response to peg-INF-alpha/ribavirin, suggesting MT-driven immune activation as pathway of HIV/HCV co-infection and response to therapy.

Introduction

Up to 25–50% of HIV-positive patients are co-infected with HCV [1,2]. In the setting of HIV disease, clinical manifestations of HCV infection are severe, leading to rapid liver damage and cirrhosis [3–8]. Indeed, liver-related mortality is a leading cause of death in HIV-infected population [9–11]. Following current standard treatment of HCV infection with pegylated-interferon-alpha (peg-INF-alpha) plus ribavirin, HIV mono-infected patients reach a sustained virologic response (SVR) with eradication of the virus in 50–80% of cases; conversely, the rate of SVR is substantially lower in HIV/HCV co-infected subjects [12,13]. Despite several factors have been associated with response to anti-HCV therapy, the determinants of successful outcome of full course peg-INF-alpha/ribavirin therapy are still scantily defined [14–18].

No HCV-RNA decrease ≥2 log10 after 3 months of treatment, that is called “null response” (NR), is associated with a >95% probability of no sustained response and has recently been associated with a very low response to retreatment with triple therapies including peg-INF-alpha/ribavirin/anti-HCV protease inhibitors [18–22]. Conversely, HCV-RNA decrease ≥2 log10 after 3 months of treatment, i.e. Early Virologic Response (EVR), has a positive predictive value on SVR of 72–84% [19,20].

During HIV infection, a dramatic depletion of CD4+ T cells in the gut occurs [23], leading to the speculation that injury to the immune component of the gastrointestinal mucosal surface may induce increased translocation of microbial products in the systemic circulation, particularly LPS, despite a direct cause-effect nexus between gut mucosa disruption and microbial translocation has not been established yet [24]. Increased levels of circulating
LPS correlate with immune activation, in turn playing a key role in the pathogenesis of disease progression and CD4+ lymphopenia [24–26].

Recently, the role of LPS has also been analyzed as a possible underlying cause of liver disease. Subjects with HCV monoinfection display a high degree of microbial translocation (MT) and elevated LPS levels are strongly associated with the severity of liver disease [27,28]; likewise, augmented plasma LPS also features non-alcoholic fatty liver disease [29–31]. Furthermore, in animal models LPS appears to accelerate liver fibrosis, both directly by increasing hepatic fibrosis and stimulating liver Kupffer cells, and indirectly by enhancing immune activation [32,33].

Given the importance of early predictive parameters of therapeutic efficacy, and above all, of EVR, in order to limit the frequent side effects of drug exposure in patients unlikely to benefit from treatment, we sought to investigate whether measures of MT before the initiation of anti-HCV treatment correlates with EVR and/or SVR to HCV therapy in HIV/HCV co-infected patients.

Materials and Methods

Study design and population

We retrospectively analyzed chronic HIV/HCV co-infected patients attending the Institute of Infectious and Tropical Diseases, University of Brescia at “Spedali Civili”, Brescia and the Clinic of Infectious Diseases, University of Milan at “San Paolo” Hospital in Milan, Italy between January 2005 and December 2009. This study was approved by the Ethnic Committees of the University of Brescia at “Spedali Civili”, Brescia and of the University of Milan at “San Paolo” Hospital. Each patient gave written informed consent to blood collection for research purpose, upon approval of the form by Local Ethnic Committee.

Inclusion criteria were to have initiated at least one dose of a treatment including peg-INF-alpha 2a and 2b subcutaneously once weekly (190 mcg or 1.5 mcg/Kg) plus daily weight-dosed ribavirin (1000 mg/day for a pretreatment weight <75 Kg or 1200 mg/day for weight ≥75 Kg).

According to the virological response at week 12 of treatment, patients were considered: (i) Early Virological Responders (EVR), undetectable serum HCV-RNA (<50 IU/mL) or ≥2 log10 reduction from baseline after 12 weeks of therapy; (ii) Null Responders (NR), serum HCV-RNA ≥50 IU/mL and <2 log10 reduction from baseline.

SVR was defined as undetectable serum HCV-RNA (<50 IU/mL) 24 weeks after the end of a full course of 48 or 72 weeks of anti-HCV treatment, according to genotype. Baseline was defined as time of anti-HCV treatment introduction (within one month before the beginning of therapy). Subjects who were lost at follow-up before week 12 or before the time point established for SVR assessment were considered NR patients and Sustained Virological Non Responders (N-SVR patients), respectively.

Stageing of liver disease

The stage of liver disease was determined in a subgroup of patients who underwent percutaneous liver biopsies, or liver stiffness by transient elastography (FibroScan®, Echo Sense Paris, France). Only the examinations with an Interquartile Range below 30% of the median value and a success rate of acquisition above 60% were considered [34]. The Ishak-modified Knodell score system (2000) was used to assess necro-inflammatory activity and fibrosis. Advanced fibrosis was defined as Knodell score F3–4 on liver biopsy or liver stiffness greater than 12.5 kPa on Fibroscan. Hepatic cirrhosis was defined as the presence of a histopathological diagnosis, a liver surface nodularity assessed by ultrasound or a liver stiffness greater than 17 kPa.

MT and immune activation analysis

LPS and sCD14 plasma levels were quantified on fasting samples with commercially available kits (Limulus Amebocyte Assay, Cambrex, Italy; ELISA assay, R&D, Milan, Italy) as previously described [25].

Activated HLA-DR+CD38+CD4+/CD8+ were evaluated on thawed PBMCs: HLA-DR fluorescent isothiocyanate (FITC), CD38 phycoerythrin (PE), CD4 PerCP/Cy5.5 (PerCP/Cy 5.5), CD8 PerCP/Cy5.5 (PerCP/Cy 5.3) (Becton Dickinson, San José, CA, USA). The following combinations were used: CD4/HLA-DR/CD38, CD8/HLA-DR/CD38. The proportion of HLA-DR+CD38+ was calculated on gated CD4+ and CD8+ T-cells.

Statistical analysis

Baseline differences between patients’ groups were assessed using Mann-Whitney non-parametric U test and Chi-squared test for continuous and categorical variables, respectively. Comparison of MT and immune activation between patients with HCV genotypes 1–4 versus 2–3, absence-moderate versus advanced fibrosis, cirrhosis versus not cirrhosis, EVR versus NR and SVR versus N-SVR patients were evaluated by Mann-Whitney U test. Multivariable logistic regression model was used to identify baseline parameters that were independently associated with EVR or SVR. Multivariate analysis was performed in 65/98 patients for whom all the clinical, epidemiological and biological parameters under study were available. Factors considered in the logistic regression model were age, sex, baseline CD4+ T cell count, HCV genotypes, HCV-RNA, fibrosis, cirrhosis and MT.

Analyses were performed using SPSS software (version 18).

Results

Study population

Ninety-eight HIV/HCV co-infected patients undergoing anti-HCV treatment were enrolled. Table 1 shows the clinical, epidemiological, and laboratory data of the patients under study. 71 patients (72.5%) achieved EVR; 27 subjects (27.5%) displayed NR. Eight out of 98 patients stopped HCV therapy before 12 weeks and were lost at follow up (Table 1).

Patients’ groups were comparable for demographic, HIV related variables, and metabolic parameters (Table 1).

MT and HCV related parameters

Plasma LPS and sCD14 levels were assessed in a subgroup of unselected patients for whom plasma samples were available (65 and 91 samples, respectively). Baseline characteristics of the 65 and 91 patients for whom LPS and sCD14 measurements were performed were comparable to the main population under study.

Compared to initial-moderate hepatic disease, the presence of advanced hepatic fibrosis was not associated with higher sCD14 levels [median sCD14, patients with advanced hepatic fibrosis: 3, (IQR 2.53–3.66) - patients with initial-moderate hepatic disease: 2.77, (IQR 2.25–3.48), p = 0.128], (Figure 1a).

Patients with cirrhosis were characterized by a trend to higher sCD14 plasma levels, albeit not reaching statistical significance [median sCD14, patients with cirrhosis: 3.09, (IQR 2.62–4.22) - patients without cirrhosis: 2.79, (IQR 2.29–3.44), p = 0.052], (Figure 1c).

Similarly, patients with HCV genotypes 1–4 tended to display higher sCD14 [median sCD14, HCV genotype 1–4: 3.07, (IQR
Table 1. Baseline demographic and immuno-virological characteristics of study population.

| Characteristics                                                                 | Patients (98) | EVR (71) | NR (27) | p (EVR vs NR) |
|--------------------------------------------------------------------------------|---------------|---------|---------|---------------|
| Age, years *                                                                   | 44 (41–46)    | 44 (41–46) | 43 (40–46) | 0.461         |
| Gender, male *                                                                 | 81 (82.7)     | 57 (60.3) | 24 (88.9) | 0.385         |
| Time since 1st diagnosis of HIV, (years) *                                      | 18 (13–20)    | 18 (13–21) | 19 (12–20) | 0.466         |
| Duration of cART, (years) *                                                     | 10 (8–13)     | 10 (8–14) | 10 (5–12) | 0.592         |
| cART *                                                                          |               |         |         | 0.845         |
| Naive                                                                            | 2 (2)         | 1 (1.5)  | 1 (3.7)  |               |
| NNRTI+NRTI                                                                      | 14 (14.3)     | 11 (15.5) | 3 (11.1) |               |
| NRTI+PI                                                                         | 74 (75.5)     | 53 (74.6) | 21 (77.8)|               |
| Other                                                                            | 8 (8.2)       | 6 (8.4)  | 2 (7.4)  |               |
| Exposure categories *                                                           |              |         |         | 0.778         |
| MSM                                                                             | 3 (3)         | 2 (2.8)  | 1 (3.7)  |               |
| WSM                                                                             | 8 (8.2)       | 5 (7)    | 3 (11.1) |               |
| IDUs                                                                            | 87 (88.8)     | 64 (90.2)| 23 (85.2)|               |
| Previous AIDS diagnosis *                                                       | 24/93 (25.8)  | 14/67 (20.9) | 10/26 (38.5) | 0.082         |
| CD4+ T cells/μL nadir *                                                         | 152 (67.5–251.5) | 173 (106.5–258.5) | 100 (36–198) | 0.045         |
| Baseline CD4+ T cells/μL *                                                      | 430 (321.5–567) | 433 (321–555) | 428 (300–687)| 0.659         |
| CD4+ T cells %                                                                  | 26.9 (21.9–33) | 27.6 (22.1–33.7) | 25 (19.9–29.1)| 0.274         |
| CD8+ T cells/μL *                                                               | 601.5 (467.5–939) | 626 (429–900) | 589 (492–1132)| 0.556         |
| CD8+ T cells %                                                                  | 40.9 (33.9–47) | 40.3 (33.6–47) | 41.2 (34.1–48.5)| 0.578         |
| Baseline HIV-RNA log_{10} cp/mL *                                               | 1.7           | 1.7      | 1.7      | 0.893         |
| Time to HIV-RNA log_{10} <40 cp/mL (months)*                                    | 41 (20–69)    | 41 (18–72.2) | 43 (20–58.7) | 0.569         |
| HCV genotypes *                                                                 |              |         |         | 0.0001        |
| 1–4                                                                             | 45 (45.9)     | 23 (32.4) | 22 (81.5) |               |
| 2–3                                                                             | 53 (54.1)     | 48 (67.6) | 5 (18.5)  |               |
| Baseline HCV-RNA log_{10} IU/mL *                                              | 5.5 (4.9–6.03) | 5.6 (4.8–5.8) | 5.8 (5.2–6.5)| 0.015         |
| Cirrhosis *                                                                     | 30/94 (31.2)  | 18/69 (26.1) | 12/25 (48)   | 0.044         |
| Advanced fibrosis *                                                             | 43/89 (48.3)  | 29/66 (43.9) | 14/23 (60.9)| 0.162         |
| HBV infection (HBsAg+) *                                                        | 7 (7.1)       | 4 (5.6)  | 3 (11.1)  | 0.390         |
| Serum AST (UI/L) *                                                              | 109.8 (42.2–94) | 67 (42–94)  | 71 (42–103) | 0.972         |
| Serum ALT (UI/L) *                                                              | 89 (55–137.2) | 97 (51–145) | 85 (58–110) | 0.548         |
| BMI *                                                                           | 22.9 (21.2–25.1) | 22.9 (21.1–25.4) | 22.8 (21.6–25.6)| 0.320         |
| Glycemia (mg/dL) *                                                              | 89 (83–97.5)  | 90 (83.7–101.7) | 88 (79.2–96.5)| 0.492         |
| Insulinemia (UI/L) *                                                            | 12.9 (9.4–20.1) | 13 (9.4–20.6) | 11 (8.1–18.2)| 0.526         |
| Alcol (gr/die) *                                                                | 0 (0–11)      | 0 (0–10) | 0 (0–5)   | 0.755         |
| HOMA index *                                                                    | 2.6 (1.7–4.1) | 2.5 (1.7–4) | 2.9 (1.6–4.3)| 0.972         |

LEGEND. Data are presented as *median, (IQR) and absolute number, (%). Differences between groups were compared by *Mann Whitney U test and *χ² test. EVR, Early Virological Response: undetectable serum HCV-RNA (<50 IU/mL) or ≥2 log_{10} reduction from baseline after 12 weeks of therapy; NR, Null Responders: serum HCV-RNA ≥50 IU/mL and <2 log_{10} reduction from baseline. cART, Combination Antiretroviral therapy; NRTI, Nucleoside Reverse Transcriptase Inhibitors; NNRTI, Non Nucleoside Reverse Transcriptase Inhibitors; PI, Protease Inhibitors. MSM, men who have sex with men; WSM, women who have sex with men; IDUs, injection drug users. HCV, hepatitis C virus; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen. AST, aspartate aminotransferase; ALT, alanine aminotransferase. BMI, Body Mass Index. HOMA index, Homeostatic Model Assessment index.

doi:10.1371/journal.pone.0032028.t001
Figure 1. Higher microbial translocation is associated with HCV genotypes 1–4 and cirrhosis. a)-b) sCD14 and LPS were compared between patients with advanced fibrosis (AF) and non advanced fibrosis (N-AF). c)-d) sCD14 and LPS were compared between patients with cirrhosis and absence of cirrhosis (N-Cirrhosis). e)-f) sCD14 and LPS were compared between patients with HCV genotypes 1–4 and genotypes 2–3. Each point represents the value from one subject’s plasma. sCD14 and LPS were measured in plasma samples; sCD14 μg/mL, LPS pg/mL. AF = advanced fibrosis – N-AF = non advanced fibrosis. p-values were assessed by Mann Whitney U test. p < 0.05 was considered non significant (NS).

doi:10.1371/journal.pone.0032028.g001
T cell activation and HCV related parameters

We studied HLA-DR and CD38 expression on CD4+ and CD8+ T cells in an unselected subgroup of 53 patients for whom PBMC samples were available. Baseline characteristics of this subgroup of patients were comparable to the main population under study.

Compared activated T cell numbers were shown in patients with advance fibrosis compared to those with absent or initial-moderate fibrosis [HLA-DR+/CD38+/CD4+, advanced fibrosis: 30.8, (IQR 13.9–46.8) - absence or initial-moderate fibrosis: 25.8, (IQR 16.2–43.5), p = 0.957; HLA-DR+/CD38+/CD8+, advanced fibrosis: 39.9, (IQR 21.8–63.8) - absence or initial-moderate fibrosis: 41.01, (IQR 28.5–53.2), p = 0.513] [Figure 2a, b] and in patients with cirrhosis compared to subjects not displaying cirrhosis [HLA-DR+/CD38+/CD4+, cirrhosis: 28.9, (IQR 13.3–47.8) - absence of cirrhosis: 25.8, (IQR 16.2–44.1), p = 0.971; HLA-DR+/CD38+/CD8+, cirrhosis: 41.9, (IQR 23.6–69.2) – absence of cirrhosis: 41.1, (IQR 27.1–56.2), p = 0.62] (Figure 2c, d).

Similarly activated CD4+ and CD8+ T cell proportions were shown by patients with genotypes 1–4 and patients with genotypes 2–3 [HLA-DR+/CD38+/CD4+, genotypes 1–4: 25.26, (IQR 15.94–45.7) - genotypes 2–3: 31.34, (IQR 14.94–44.47), p = 0.906; HLA-DR+/CD38+/CD8+, genotypes 1–4: 39.95, (IQR 26.94–58.21) - genotypes 2–3: 41.53, (IQR 22.39–58.7), p = 0.914] (Figure 2e, f).

Immune activation and MT according to EVR to anti-HCV treatment

To address the association of peripheral T cell activation with the outcome of peg-IFN-alpha/ribavirin anti-HCV treatment, we also analyzed HLA-DR and CD38 expression on CD4+ and CD8+ T cells in EVR and NR patients.

Median HLA-DR+/CD38+/CD4+ and CD8+ were similar in both groups, HLA-DR+/CD38+/CD4+, EVR 34.1 (IQR 19.3–48.3) - NR 35.7 (IQR 26–66.7), p = 0.097; HLA-DR+/CD38+/CD8+, EVR 51.2 (IQR 27.2–65.9) – NR 50.5 (IQR 33.2–76.1), p = 0.309] (Figure 3a, b).

In addition, to assess potential interactions between MT and virological response to anti-HCV treatment, baseline LPS and sCD14 levels were compared between EVR subjects and NR (Figure 4a, b). Interestingly, EVR patients presented significantly lower median sCD14 EVR 2.73, IQR: 2.18–3.25 – NR 3.3, IQR: 2.9–4.4, p = 0.0001] (Figure 4a), despite no differences in median LPS levels between patients (EVR 178.7, IQR: 150.7–298.3 – NR 197.7, IQR: 80.4–327.4, p = 0.865), (Figure 4b).

Identification of factors associated to EVR to anti-HCV treatment

Given that the host response to MT expressed by sCD14 was associated with a reduced probability of reaching EVR (OR 0.419 for each sCD14 unit more, 95% CI 0.252–0.695, p = 0.0001), whereas no association was shown between LPS and EVR (OR 1.000 for each LPS unit more, 95% CI 0.996–1.004, p = 0.934). As expected, HCV genotypes 1–4 (OR 0.109 versus HCV genotypes 2–3, 95% CI 0.037–0.324, p = 0.0001), higher HCV viral load (OR 0.409 for each log10 IU/mL more, 95% CI 0.207–0.809, p = 0.01), and cirrhosis (OR 0.382 versus absence of cirrhosis, 95% CI 0.148–0.99, p = 0.048) were all associated to a decreased chance of EVR (Table 2).

In line with univariate data, the proportion of patients with cirrhosis were more likely to fail EVR (cirrhosis/NR = 46%, cirrhosis/EVR = 26%, p = 0.044); similarly a higher proportion of genotype 1–4 patients did not reach EVR (genotype 1–4/ NR = 61%, genotype 1–4/EVR = 32%, p = 0.0001). No differences were shown in EVR/NR according to the presence fibrosis (p = 0.162).

Significantly predictive parameters in the univariate analysis entered the logistic regression model adjusted for age, sex and baseline CD4+ T cell count (Table 2).

Overall, multivariate analysis shown in Table 2 was performed in 65/90 patients for whom both LPS and sCD14 data were available. Baseline characteristics of these 65 patients were comparable to the entire cohort.

In the adjusted model, higher sCD14 levels (AOR 0.145 for each unit more, 95%CI 0.031–0.688, p = 0.015) was confirmed as predictive independent marker of decreased chances of EVR (Table 2). No other demographic or HCV related variable that we studied resulted independently associated with EVR (Table 2).

Similar results were obtained also excluding from the analyses the 8/98 patients who did not reach 12 weeks follow up (data not shown).

Baseline characteristics of the study population according to SVR

SVR data were available for 88 subjects. Ten patients have not reached the end of the study at the time of analysis.

Overall, 41 patients (46.6%) exhibited SVR. Table 3 shows the clinical, epidemiological, and laboratory data of the patients under study according to SVR. Patients achieving and not achieving SVR were comparable for baseline demographic parameters (Table 3).

In fact, even if baseline CD4+ T cells were similar, SVR subjects presented higher CD4+ nadir and higher current CD8+, compared to N-SVR (median, IQR: nadir CD4+ T cells SVR 212/μL, 120–268 – N-SVR 131/μL, 45–198, p = 0.025; CD8+ T cells SVR 693/μL, 538–1048.5 – N-SVR 540/μL, 303–952, p = 0.030) (Table 3).

Similarly to EVR patients, SVR subjects were characterized by a baseline milder liver disease: in fact, in comparison with N-SVR patients, they showed lower baseline median HCV viremia (HCV-RNA, 5.3 log10 cp/mL, IQR: 4.7–5.9 versus 5.68 log10 cp/mL, IQR: 5.3–6.2; p = 0.014) and they more rarely presented cirrhosis (9/41, 22% vs 19/44, 43%, p = 0.037). In the same way, HCV genotypes 1–4 were more represented in N-SVR patients (SVR 7, 17% - N-SVR 33, 70%, p = 0.0001) (Table 3).

We then investigated the predictive value of EVR on SVR in our patients: the positive predictive value of EVR for the achievement of SVR was 64.1% (41 EVR patients who reached SVR/64 EVR patients who reached the end of the study), on the contrary the negative predictive value was 100% (all 24 NR did not show sustained virological response).

T cell activation, MT and host response to MT according to SVR to anti-HCV treatment

Peripheral T lymphocytes activation was similar in both groups (HLA-DR+/CD38+/CD4+, SVR 30.8 (IQR 18.1–39.2) – N-SVR 25.3 (IQR 15.3–34), p = 0.933; HLA-DR+/CD38+/CD8+, SVR 41 (IQR 29.3–56.6) – N-SVR 40 (IQR 26.5–62.5), p = 0.855) (Figure 3c, d).

On the contrary, SVR patients were characterized by lower sCD14 and LPS levels, reaching statistical significance for sCD14
Figure 2. Activated HLA-DR+CD4+ and CD8+ T-cells according to liver fibrosis, cirrhosis and HCV genotypes. a)-b) Activated HLA-DR+CD4+ and CD8+ T-cells were compared between patients with advanced fibrosis (AF) and non advanced fibrosis (N-AF). c)-d) Activated HLA-DR+CD4+ and CD8+ T-cells were compared between patients with cirrhosis and absence of cirrhosis (N-Cirrhosis). e)-f) Activated HLA-DR+CD4+ and CD8+ T-cells were compared between patients with HCV genotypes 1–4 and genotypes 2–3. Each point represents the value from one subject’s plasma. Activated HLA-DR+CD4+ and CD8+ T-cells % values are presented. AF = advanced fibrosis – N-AF = non advanced fibrosis. p-values were assessed by Mann Whitney U test. p > 0.05 was considered non significant (NS).

doi:10.1371/journal.pone.0032028.g002
Identification of predictors of SVR to anti-HCV treatment

To investigate the possible predictive value of MT on SVR, we conducted a logistic regression analysis including HIV and HCV related variables and both LPS and sCD14 (Table 4).

Interestingly, in the univariate model, higher circulating sCD14 and LPS are associated with a reduced chance of SVR, reaching significance for sCD14 (OR 0.668 for each sCD14 unit more, 95%CI 0.428–1.041, p = 0.046; OR 0.996 for each LPS unit more, 95%CI 0.990–1.001, p = .106). In addition, several HCV parameters were related to SVR: HCV genotypes 1–4 (OR 0.087 versus HCV genotypes 2–3, 95%CI 0.001–0.469, p = 0.014). No further measures of MT and immune response to MT that we measured were independently associated with SVR (Table 4).

We next performed multivariate analysis in 65/98 patients for whom both LPS and sCD14 data were available (Table 4). Baseline characteristics of these 65 patients were comparable to the entire cohort. In multivariate logistic regression, the most important predictive parameter of SVR was HCV genotype (AOR 0.022 HCV genotypes 1–4 versus 2–3, 95%CI 0.001–0.469, p = 0.014). No further measures of MT and immune response to MT that we measured were independently associated with SVR (Table 4).

Similar results were obtained also excluding from the analyses the 0/90 patients who were lost at follow up before 12 weeks (data not shown).

Results were similar in a sensitivity analysis including only HIV/HCV co-infected patients on HAART (n = 96); despite comparable LPS, EVR patients presented lower sCD14 than NR (median, IQR: sCD14 EVR 2.74, 2.18–3.26 – NR 3.75, 2.89–4.13, p = 0.0001; LPS EVR 178.7, 150.7–321.9 – NR 193.0, 75–321.9, p = 0.649 (Figure S1a, b).
Accordingly, lower sCD14 was displayed by SVR as compared to N-SVR (median, IQR: sCD14 SVR 2.63, 2.15–3.37 – N-SVR 3.06, 2.48–3.87, p = 0.041; LPS SVR 173.9, 151.6–243.9 – N-SVR 214.1, 145.3–329.5, p = 0.213) (Figure S1c, d).

Furthermore, sCD14 confirmed independently associated with EVR (Tables S1 and S2).

**Discussion**

In cART-treated HIV/HCV co-infected patients we show: (i) greater host responsiveness to LPS in patients with most aggressive HCV-related liver disease and harboring HCV genotypes 1–4; (ii) low levels of LPS/sCD14 as predictors of virological response to 3 months of anti-HCV treatment (i.e. EVR).

Response to anti-HCV therapy is less satisfactory in HIV/HCV co-infected individuals, urging the identification of predictive outcome markers.

There is increasing evidence that MT and MT-driven immune activation are pathogenetic mechanisms of alcohol-driven liver disease [35,36], and of hepatic disease progression in HBV and HCV mono-infection as well as in HIV/HCV co-infection [27,33].

In line with this hypothesis, our data show that HIV/HCV co-infected patients with cirrhosis display higher circulating sCD14 that is a marker of MT-driven immune activation [24,27].

Having shown the association between heightened circulating sCD14 and most advanced liver disease, we next aimed to investigate whether MT and the host response that it elicits could condition short- and long-term virological outcome to anti-HCV treatment.

Our major finding is that, despite equal MT in HIV/HCV co-infected patients with and without EVR, a contained host response to translocated microbial by-products as measured by low levels of circulating sCD14, independently predicts EVR.

As for HCV-related factors, only HCV genotype was confirmed to independently affect response to antiviral treatment. Although the effect of HCV genotypes on HCV/HIV pathogenesis, disease progression and response to therapy are largely unknown, genotypes 1–4 are commonly defined as difficult-to-treat given the much lower probability of response to conventional HCV therapy [37,38]. Interestingly, patients displaying HCV genotypes 1–4 also presented elevated sCD14 levels. This association remained significant also excluding from the analysis patients characterized by severe forms of liver disease, suggesting that
difficult-to-treat HCV genotypes might per se associate to heightened immune activation, possibly due to MT.

Immune activation has been suggested to accelerate liver disease in HIV/HCV co-infection, in turn limiting response to therapy [13,39,40]. In our study, activated HLA-DR+CD38+ T cells were increased in comparison with levels of HIV mono-infected patients and healthy subjects reported in literature [41], and yet they failed significant association with HCV genotypes, liver disease and virological response to anti-HCV treatment.

On the contrary, by showing higher sCD14 levels in NR patients, our data indicate enhanced activation of innate immunity as possible correlate of failing response to therapy, that might be secondary to increased MT.

However, should MT be indeed a relevant pathway in this context, it might be speculated within the liver that fails to be detected by means of peripheral blood investigation. According to this model, Sandler et al. recently described high density of CD14+CD66+ in the liver of mice and suggested that this might be speculated within the liver that fails to be detected by means of peripheral blood investigation. According to this model, Sandler et al. recently described high density of CD14+CD66+ in the liver of patients with liver cirrhosis.

### Table 2. Association between markers of microbial translocation and Early Virological Response to anti-HCV treatment.

|                      | Univariate |         | Multivariate |
|----------------------|------------|---------|--------------|
|                      | OR 95%CI   | P       | AOR 95%CI    |
| **LPS (pg/mL)**      | 1.000 0.996–1.004 0.934 | 0.997 0.99–1.004 0.345 |
| sCD14 (µg/mL)        | 0.419 0.252–0.695 0.001 | 0.145 0.031–0.688 0.015 |
| HCV genotypes (1–4 vs 2–3) | 0.109 0.037–0.324 0.0001 | 0.233 0.021–2.618 0.238 |
| HCV-RNA (log10 IU/mL) | 0.409 0.207–0.809 0.01 | 0.789 0.134–4.628 0.793 |
| Fibrosis (advanced vs non advanced) | 0.504 0.191–1.327 0.165 | 0.134 0.005–3.879 0.616 |
| Cirrhosis (yes vs no) | 0.382 0.148–0.99 0.048 | 0.185 0.007–4.623 0.304 |
| Nadir CD4+ T cells/µL | 1.003 0.999–1.006 0.155 | 1.007 0.998–1.016 0.134 |
| CD4+ T cells/µL | 0.999 0.997–1.002 0.518 | 0.996 0.990–1.001 0.112 |
| Age, years | 1.043 0.948–1.149 0.386 | 1.134 0.879–1.463 0.333 |
| Sex, male vs female | 0.509 0.134–1.934 0.321 | 0.215 0.007–6.926 0.385 |

**LEGEND.** LPS, soluble CD14, CD4+ T cells/µL, age, HCV-RNA log10 cp/mL for each unit more. sCD14 and LPS were measured in plasma samples; sCD14 µg/ mL, LPS pg/mL. Multivariate analysis was performed in 65/98 patients for whom all the clinical, epidemiological and biological parameters under study were available. OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval. p>0.05 was considered non significant.

doi:10.1371/journal.pone.0032028.t002

### Table 3. Baseline demographic and immuno-virological characteristics of patients according to SVR.

| Characteristics | SVR (41) | N-SVR (47) | p |
|-----------------|----------|------------|---|
| Age, years *    | 44 (40–47.5) | 43 (42–46) | 0.997 |
| Gender, male    | 33 (80)  | 40 (85)    | 0.565 |
| Time since 1st diagnosis of HIV, (years)* | 18 (13–22) | 18 (15–20) | 0.700 |
| Duration of HAART, (years) * | 10 (5–14) | 11 (9–13) | 0.192 |
| HAART            |          |            | 0.649 |
| naive           | 1 (2)    | 1 (2)      | |
| NNRTI+NNRTI     | 7 (17)   | 5 (11)     | |
| NRTI+PI         | 30 (73)  | 37 (79)    | |
| other           | 3 (7)    | 4 (8)      | |
| Exposure catechegies* |          | 0.300 |
| MSM             | 2 (5)    | 0          | |
| WSM             | 2 (5)    | 3 (6)      | |
| IDUs            | 37 (90)  | 44 (94)    | |
| Previous AIDS diagnosis * | 8/39 (21) | 13/44 (30) | 0.345 |
| CD4+ T cells/µL nadir * | 131 (45.2–198) | 0.025 |
| Baseline CD4+ T cells/µL * | 467 (336.5–574) | 0.281 |
| CD4 T cells % * | 26.3 (21.5–32.1) | 27.5 (20–34) | 0.977 |
| CD T cells/µL * | 693 (558–1048.5) | 540 (383–952) | 0.030 |
| CD T cells % * | 41.1 (35.8–49.5) | 40.4 (33.6–47) | 0.315 |
| Baseline HIV-RNA log10 cp/mL * | 1.7 | 1.7 | 0.934 |
| Time to HIV-RNA <40 cp/mL (mts)* | 43 (15–72) | 42 (21–69) | 0.986 |
| HCV genotypes * | 0.0001 | |
| 1–4             | 7 (17)   | 33 (70)    | |
| 2–3             | 36 (88)  | 14 (30)    | |
| Baseline HCV-RNA log10 IU/mL * | 5.3 (4.7–5.9) | 5.68 (5.3–6.2) | 0.014 |
| Cirrhosis       | 9/41 (22) | 19/44 (43) | 0.037 |
| Advanced fibrosis* | 15/39 (38) | 23/41 (56) | 0.114 |
| HBV infection (HbsAg)+ * | 2 (5) | 4 (9) | 0.681 |
| Serum AST (UI/L) * | 69 (44–94.5) | 69 (42–103) | 0.812 |
| Serum ALT (UI/L)* | 97 (56–170) | 85 (55–127) | 0.268 |
| BMI * | 22.3 (21.1–24.5) | 23.1 (21.2–25.2) | 0.495 |
| Glycemia (mg/dL) * | 89 (82–93) | 83 (97–93) | 0.740 |
| Insulinemia (UI/L) * | 12.4 (7.1–20.3) | 13.4 (9.7–21.2) | 0.713 |
| Alcol (gr/die) * | 0 (0–20) | 0 (0–5) | 0.611 |
| HOMA index * | 2.3 (1.5–3.8) | 3.1 (1.8–4.6) | 0.190 |

**LEGEND.** Data are presented as *median, IQR* and *absolute number, (%). Differences between groups were compared by *Mann Whitney U test and *χ² test. N-SVR, Non Sustained Virological Response: serum HCV-RNA (≥50 IU/mL) 24 weeks after the end of a full course of 48 or 72 weeks of anti-HCV treatment. SVR, Sustained Virological Response: undetectable serum HCV-RNA (<50 IU/mL) 24 weeks after the end of a full course of 48 or 72 weeks of anti-HCV treatment. NNRTI, Nucleoside Reverse Transcriptase Inhibitors; NNRTI, Non Nucleoside Reverse Transcriptase Inhibitors; PI, Protease Inhibitors; MSM, men who have sex with men; WSM, women who have sex with men; IDUs, injection drug users; HCV, hepatitis C virus; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; BMI, Body Mass Index. HOMA index, Homeostatic Model Assessment index. doi:10.1371/journal.pone.0032028.t003
The liver correlating with hepatic disease progression, strongly suggestive for LPS-driven activation of hepatic Kupffer cells [27].

Our findings suggest that the host response to increased MT might play a central role in the pathogenesis of HIV/HCV-related liver injury, and in the inappropriate response to therapy, allowing to speculate a vicious cycle, whereby HIV effects on the gut mucosa might enhance MT which stimulate hepatic fibrosis/cirrhosis with consequent portal systemic shunt, further fueling MT.

However, when we investigated the independent effect of MT on long-term response to therapy, sCD14 was still associated to SVR in the univariate analysis, but lost independent predictive value in the multivariable model, suggesting that immune response to MT might play a role in the earlier phases of treatment. Because EVR conditions SVR, this could underline the importance of assessing (and controlling) MT before starting anti-HCV therapy.

In the present study, we analysed only circulating sCD14 as marker of microbial translocation and its downstream effects of immune activation in the setting of HCV infection and disease. In particular, our findings expands on data by both by Sandler et al. in HCV mono-infected patients showing elevated circulating sCD14 as independent predictor of end-stage liver disease [27], and Balagopal et al. in HIV/HCV co-infected patients correlating elevated sCD14/LPS with cirrhosis [33], as they strongly suggest an independent influence of immune activation due to MT in the outcome of anti-HCV treatment.

A further limitation of our research is that, despite associating with EVR, augmented sCD14 seemingly fail to influence sustained response to therapy, in turn limiting its exploitation in the clinical practice as measure to a priori include/exclude patients from treatment.

Knowing the prognostic significance of EVR for SVR, larger studies are needed to shed light on MT in HIV/HCV co-infection pathogenesis and response to therapy, essential premise to evaluate the possibility of novel therapeutic adjuvant interventions targeting translocation of bacterial products in peripheral blood ant its downstream effects.

**Supporting Information**

**Figure S1** Circulating sCD14 and LPS levels are higher in NR and in N-SVR patients on HAART. Results from a sensitivity analysis including only HIV/HCV co-infected patients on HAART (n = 96) are shown. a-b) sCD14 and LPS were compared between patients with early virological response [EVR, i.e. undetectable serum HCV-RNA (<50 IU/mL) or ≥2 log10 reduction from baseline after 12 weeks of therapy], and Null Responders (NR) [i.e. serum HCV-RNA ≥50 IU/mL and <2 log10 reduction from baseline]. c-d) sCD14 and LPS were compared between patients with sustained virological response [SVR, i.e. undetectable serum HCV-RNA (<50 IU/mL) 24 weeks after the end of a full course of 48 or 72 weeks of anti-HCV treatment, according to genotype], and N-SVR subjects. (TIF)

**Table S1** Association between markers of microbial translocation and Early Virological Response to anti-HCV treatment on patients on HAART. Univariate and multivariate logistic regression conducted including only HIV/HCV patients on HAART (n = 96) to explore association between markers of microbial translocation (sCD14 and LPS) and EVR. The multivariate analysis is adjusted for demographic, HCV- and HIV-related variables. LPS, soluble CD14, CD4+ T cells/µL, age, and sex are included in the model.

---

**Table 4. Association between markers of microbial translocation and Sustained Virological Response to anti-HCV treatment.**

|                      | Univariate       | Multivariate      |
|----------------------|------------------|-------------------|
|                      | OR    | 95%CI | p     | AOR   | 95%CI | p     |
| LPS (pg/mL)          | 0.996 | 0.990–1.001 | 0.106 | 1.000 | 0.980–1.003 | 0.129 |
| sCD14 (µg/mL)        | 0.688 | 0.428–1.041 | 0.046 | 0.584 | 0.214–1.589 | 0.292 |
| HCV genotypes (1–4 vs 2–3) | 0.087 | 0.031–0.244 | 0.0001 | 0.022 | 0.001–0.469 | 0.014 |
| HCV-RNA (log10 IU/mL) | 0.423 | 0.224–0.798 | 0.008 | 0.778 | 0.309–10.231 | 0.519 |
| Fibrosis (advanced vs non advanced) | 0.498 | 0.200–1.194 | 0.116 | 0.553 | 0.026–11.663 | 0.703 |
| Cirrhosis (yes vs no) | 0.370 | 0.143–0.957 | 0.040 | 0.161 | 0.007–4.472 | 0.289 |
| Nadir CD4+ T cells/µL | 1.003 | 1.000–1.006 | 0.071 | 1.005 | 0.997–1.014 | 0.835 |
| CD4+ T cells/µL      | 1.001 | 0.999–1.003 | 0.287 | 1.000 | 0.995–1.009 | 0.669 |
| Age, years           | 0.999 | 0.908–1.093 | 0.996 | 0.942 | 0.719–1.236 | 0.870 |
| Sex, male vs female  | 0.722 | 0.237–2.200 | 0.566 | 0.812 | 0.067–9.871 | 0.216 |

**LEGEND.** LPS, soluble CD14, CD4+ T cells/µL, age, HCV-RNA log10 IU/mL for each unit more. sCD14 and LPS were measured in plasma samples; sCD14 µg/mL, LPS pg/mL. Multivariate analysis was performed in 65/98 patients for whom all the clinical, epidemiological and biological parameters under study were available. OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval. p>0.05 was considered non significant.

doi:10.1371/journal.pone.0032028.t004
HCV-RNA log_{10} cp/mL for each unit more, sCD14 and LPS were measured in plasma samples; sCD14 ng/μL, LPS pg/mL. OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval. p = 0.05 was considered non significant.

(DOC)

Table S2 Association between markers of microbial translocation and Sustained Virological Response to anti-HCV treatment on patients on HAART. Univariate and multivariate logistic regression conducted including only HIV/HCV patients on HAART (n 96) to explore association between markers of microbial translocation (sCD14 and LPS) and SVR. The multivariate analysis is adjusted for demographic, HIV- and HIV-related variables. LPS, soluble CD14, CD4+ T cells/μL, age, HCV-RNA log_{10} cp/mL for each unit more. sCD14 and LPS were measured in plasma samples; sCD14 ng/μL, LPS pg/mL. OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval. p = 0.05 was considered non significant.

(DOC)

References

1. Rockstroh JK, Mcroft A, Soriano V, Tural C, Losso MH, et al. (2005) Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 192: 992–1002.

2. Soriano V, Mcroft A, Rockstroh J, Ledergerber B, Kinyo B, et al. (2008) Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 198: 1337–1344.

3. Bai A, McGovern B, Dhar R, Stone D, McGowan K, et al. (2001) Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus. Clin Infect Dis 32: 492–497.

4. Graham CS, Baden LR, Yu E, Mrus JM, Carine J, et al. (2001) Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 33: 362–369.

5. Rosenzohl E, Salmon-Céron D, Lewellen C, Bourdoup L, Pialoux G, et al. (2009) Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMICVIT Joint Study Group Network (Moravia 2005 study in collaboration with the Moravia 2005 surve, ANRS EN19). HIV Med 10: 202–289.

6. Puoti M, Prestini K, Putzolu V, Zanini B, Biaagara E, et al. (2003) HIV/HCV co-infection: natural history. J Biol Regul Homeost Agents 17: 144–146.

7. Bruno R, Sacchi P, Puoti M, Soriano V, Ficile G (2002) HCV chronic hepatitis in patients with HIV: clinical management issues. Am J Gastroenterol 97: 1598–1606.

8. Bruno R, Sacchi P, Puoti M, Masoichi L, Patruno S, et al. (2007) Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. J Acquir Immune Defic Syndr 46: 297–303.

9. Blackard JT, Sherman KE (2008) HCV/HIV co-infection: time to re-evaluate their precious help in the conduct of the study. We are grateful to all patients and their families for the participation in the study.

Acknowledgments

We are grateful to all patients and their families for the participation in the study.

We would like to acknowledge all the staff at the Institute of Infectious Diseases, “San Paolo” Hospital, University of Milan, and at the Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy for their precious help in the conduct of the study.

Presented in part: 17th Conference on Retroviruses and Opportunistic infections (CROI), February 16–19 2010, S. Francisco, CA, USA, Abstract #654

Author Contributions

Conceived and designed the experiments: GM PN MP Adm GC. Performed the experiments: GMB FG F. Borghi. Analyzed the data: F. Bai CT GM MP Adm. Contributed reagents/materials/analysis tools: GB F. Bai FG PN. Wrote the paper: GM PN F. Bai.
38. Kamal SM (2009) Hepatitis C genotype 4 therapy: increasing options and improving outcomes. Liver Int 29 Suppl 1: 39–48.
39. Kovacs A, Karim R, Mack WJ, Xu J, Chen Z, et al. (2010) Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis 201: 423–434.
40. Gonzalez VD, Landay AL, Sandberg JK (2010) Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol 135: 12–25.
41. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagens E, et al. (2003) T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 187: 1534–1543.
42. Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, et al. (2008) Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One 3: e1915.
43. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, et al. (2004) Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104: 942–947.
44. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798–801.
45. Surasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105: 7034–7039.
46. Chen L, Borezan I, Feld J, Sun J, Tannis LL, et al. (2005) Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128: 1437–1444.
47. Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, et al. (2008) Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 57: 516–524.
48. Surasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, et al. (2009) Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 29: 4841–4851.
49. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, et al. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52: 1084–1096.
50. Brettschneider J, Ecker D, Bisch A, Bahner D, Bogumil T, et al. (2002) The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b. J Neuroimmunol 133: 193–197.
51. Rempel H, Sun B, Calosing C, Pillai SK, Pulliam L (2010) Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection. AIDS 24: 1415–1423.